What POTN says Richard Goulding is doing Oct 2018:
Former CEO, Dr. Richard Goulding, assumes the new role of Chief Medical Officer, spearheading new product development and clinical testing of new proprietary products. Dr. Goulding will devote his time solely to this role, terminating any involvement with other entrepreneurial initiatives and affiliations, private or public, in the CBD industry. Dr. Goulding will focus on product development, in an effort to expand and enhance the Company’s offerings.
What POTN says Richard Goulding is doing July 2019:
PotNetwork Holdings, Inc. (OTC Pink:POTN) announces today that the company has engaged national law firms in Fort Lauderdale, Florida and Washington, D.C. to handle intellectual property matters, and for regulatory guidance on FDA submissions and related matters.
The Company engaged the law firms in order to assist in exploring and initiating the registration of trademarks and patents related to certain of its hemp-derived Diamond CBD products, and to evaluate the feasibility of FDA approval and registrations for certain products.
Dr. Richard Goulding, CEO of the Company, will spearhead the overall project in collaboration with the Company’s Scientific Advisory Board.
The Company is in the process of obtaining FINRA approval for changing its name to “BioTech Hemp, Inc.” and changing its trading symbol.
What RSHN/XYZ is doing regarding the scientific element, FDA stance, and clinical trials on CBD (from Jan 2019 pr):
We are still in the process of finalizing contracts with several CBD farming operations. We are also currently in negotiations with three different production companies for product fabrication. Among the more significant considerations provided by this operation is that it is set up to actually make the products and provide the labeling for any products, including products infused with CBD oils. We will be creating a separate and distinct product line featuring broad-spectrum organically produced cannabinoids as an alternative to the single dimensional, less efficacious CBD product offerings which are generally available from competing lines. Typically, the only cannabinoid present in most products is CBD, invariably from the use of CBD isolate. By contrast, we will be positioned to provide a broad spectrum approach to formulation of each product offered--a blend of various cannabinoids for optimum efficacy and bio-availability and product efficacy based on and tailored to each specific product application. We are convinced that CBD isolates, already being synthesized by pharmaceutical companies, relying simply on isolates, will not be sustainable as the synthetic product hits the market in greater supply, albeit at a reduced cost. By contrast, by presenting a broad spectrum approach, CBD, CBDV, CBG, CBC, CBN, CBDA, CBGA etc. (up to a 100 different cannabinoids), at various price points, we open the door to virtually unlimited number of products utilizing “blends” of various cannabinoids for specific applications using a variety of mediums. Together with blended products; superior (uniform) dispersion of cannabinoids within each product. Additionally, we seek a certified organic designation. Those with whom we are negotiating are each uniquely capable of efficiently manufacturing our products to specific requirements and specifications associated with particular ailments and medical maladies, targeted by Dr. Goulding and Dr. Bond. As science (clinical trials) and FDA regulation (labeling, processing, truth in advertising) increasingly impact the industry, those companies having already met proposed quality standards are likely to be much more sustainable than those that lack the same level of testing associated with their products--credibility will become an increasingly important factor in maintaining market share, price points and stock value. As specific scientific data from clinical trials proving positive impacts on health becomes more available, increased opportunity to market an even wider range of products is likely to follow for those with established sophistication and credibility in growing, harvesting, drying, extracting, post-extracting, and marketing organic cannabinoids particularly in the context of a branded, vertically integrated product line---backed by science at every step. Those studies will be conducted, at least in principal part, at Pillars Recovery.
“We are progressing with our hemp/nutraceutical line with the formulations having been structured, sourced and now processed for the market,” said CEO Dr. Stuart Miller. “We are very excited about these products, which will be drastically different and more effective than anything on the market thanks to the thoughtful compilation by Dr. Bond.” Dr. Richard Goulding, Chairman of the Board, stated. “The process of creating our nutraceutical/CBD entities is not as quick as many of our shareholders would prefer. I get countless emails wondering where the products are, worried that our competition is beating us to market, etc. Dr. Bond, one of the most meticulous practitioners I've ever met, is very specific about the types of herbs, the quality of the herbs, ratios, extractions, compilations and handling. Obtaining the right companies to work with us and in exactly the way it should be handled is time consuming. But so worth it. Like our CBD, always organically grown, full spectrum and nanotized where possible, so are the herbal additives. Formulating and compiling the compounds is a key to our future success and we are taking the necessary steps, however painful, to put quality above speed. The good news is, that we are getting much closer, and certainly by the time our SEC filings become effective.”
Long story short..........
What POTN says RG is doing...
Dr. Goulding will focus on product development, in an effort to expand and enhance the Company’s offerings. Dr. Goulding will spearhead the overall project......which is of intellectual property matters, and for regulatory guidance on FDA submissions and related matters, and collaboration with the scientific advisory board.
What is RSHN / XYZ
This joint venture is a unique effort to secure all areas of hemp production from cultivation to extraction and retail with an emphasis on unique products and high-quality CBD. RushNet is more focused on product development, particularly edibles and beverages. XYZ Hemp addresses the more scientific elements of these pursuits, using the same formulations as nutraceuticals. Together, they are able to facilitate the vertical integration envisioned. Both are acquiring and joint venturing with companies in all aspects of the cannabis field as they jointly pursue a full integration cannabis and hemp business model.
Products in development (New brands to sell on Diamond)
Trials in progress
Collaboration with other MDs and scientists
assistance with FDA approval via Stuart Miller
What happened to Biotech Hemp, Inc?? Cue in XYZ Hemp, Inc. / Rushnet, Inc.
Sorry this is a long post but read it all. Certainly speculation, but make your own conclusions.
Go RSHN!
